Regorafenib for Thyroid Cancer

Recruiting in Palo Alto (17 mi)

+1 other location

Overseen by Kartik Seghal, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Dana-Farber Cancer Institute

No Placebo Group

Prior Safety Data

Approved in 3 Jurisdictions

Trial Summary

What is the purpose of this trial?

This research study is studying a targeted therapy as a possible treatment for thyroid cancer. A targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific types of cancer cells with less harm to normal cells. - The name of the study intervention involved in this study is regorafenib.

Research Team

Kartik Seghal, MD

Principal Investigator

Dana-Farber Cancer Institute

Eligibility Criteria

Adults with metastatic medullary thyroid cancer who've had at least one prior targeted therapy can join this study. They must be able to take oral meds, have a life expectancy of 3+ months, and agree to use contraception. Excluded are those with recent severe bleeding, certain infections like HIV or hepatitis B/C, uncontrolled high blood pressure, known allergies to the drug being tested (regorafenib), or other serious health issues.

Inclusion Criteria

I am 18 years old or older.

I have previously received treatment specifically targeting my cancer.

My thyroid cancer has spread and was confirmed by a lab test.

Exclusion Criteria

Other investigational treatment during or within 30 days before starting study treatment.

I have a history of bleeding or clotting disorders.

I am experiencing mild to severe dehydration.

Treatment Details

Interventions

• Regorafenib (Tyrosine Kinase Inhibitor)

Trial Overview The trial is testing regorafenib as a second or third line treatment for thyroid cancer. Regorafenib is a targeted therapy designed to attack cancer cells more precisely and spare normal cells. Participants will receive this medication orally to evaluate its effectiveness against their cancer.

Participant Groups

Group I: Regorafenib Experimental Treatment 1 Intervention

Regorafenib tablets 80mg orally, once daily at predetermined dosage for 21 days per cycle

Who Is Running the Clinical Trial?

Dana-Farber Cancer Institute

Lead Sponsor

Trials

1,128

Recruited

382,000+

Dr. Benjamin L. Ebert

Dana-Farber Cancer Institute

Chief Executive Officer

MD from Harvard Medical School, PhD from Oxford University

Dr. Craig A. Bunnell

Dana-Farber Cancer Institute

Chief Medical Officer since 2012

MD from Harvard Medical School, MPH from Harvard School of Public Health, MBA from MIT Sloan School of Management

Bayer

Industry Sponsor

Trials

2,291

Recruited

25,560,000+

Founded

1863

Headquarters

Leverkusen, Germany

Known For

Pharmaceutical Innovations

Top Products

Aspirin, Aleve, Yaz, Nexavar

Bill Anderson

Bayer

Chief Executive Officer since 2023

BSc in Chemical Engineering from the University of Texas, MSc in Chemical Engineering and Management from MIT

Michael Devoy

Bayer

Chief Medical Officer since 2014

MD, PhD